Biotech Values

[DewDiligence]

ARIA—Regardless of marketing approval, I think [Ponatinib] will quickly become de facto second line.

I don’t necessarily disagree; however, I think it’s dangerous and premature to say (as Peter is doing) that third-party payers will be required to pay for Ponatinib no matter how expensive it may be because there is no alternative.